ストックスクリーナーアプリを入手
38.13
1.09%
0.41
プレマーケット:
38.31
0.18
+0.47%
前日終値:
$37.72
開ける：
$37.8
24時間の取引高:
1.12M
Relative Volume:
0.75
時価総額：
$2.05B
収益：
-
当期純損益:
$-38.99M
株価収益率:
-12.72
EPS:
-2.9966
ネットキャッシュフロー:
$-24.94M
1週間 パフォーマンス:
-7.02%
1か月 パフォーマンス:
-9.47%
6か月 パフォーマンス:
-45.19%
1年 パフォーマンス:
-14.20%
1日の値動き範囲:
$37.71
$39.27
1週間の範囲:
$32.63
$41.86
52週間の値動き範囲:
$32.63
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
名前
Soleno Therapeutics Inc
セクター
電話
650-213-8444
住所
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
38.13 | 2.03B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-18 | 開始されました | Wolfe Research | Outperform |
| 2025-10-07 | 開始されました | Goldman | Buy |
| 2025-08-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-23 | 開始されました | TD Cowen | Buy |
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2024-12-02 | 繰り返されました | Robert W. Baird | Outperform |
| 2024-12-02 | 繰り返されました | Stifel | Buy |
| 2024-09-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-10 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-05 | 開始されました | Piper Sandler | Overweight |
| 2024-01-23 | 開始されました | Stifel | Buy |
| 2023-11-21 | 再開されました | Guggenheim | Buy |
| 2020-09-29 | 開始されました | Guggenheim | Buy |
| 2020-01-10 | 開始されました | Craig Hallum | Buy |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2018-02-13 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Soleno Therapeutics Inc (SLNO) 最新ニュース
Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy - Bitget
H.C. Wainwright cuts Soleno Therapeutics stock price target to $100 - Investing.com South Africa
SLNO: VYKAT XR sees rapid adoption, strong coverage, and expansion plans in rare disease markets - TradingView
SLNO: VYKAT XR's launch drives strong revenue and coverage, with expansion into Europe and new indications planned - TradingView
HC Wainwright Lowers Soleno Therapeutics (NASDAQ:SLNO) Price Target to $100.00 - MarketBeat
SLNO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vanguard Group Inc. Purchases 319,317 Shares of Soleno Therapeutics, Inc. $SLNO - MarketBeat
Rafferty Asset Management LLC Purchases 45,076 Shares of Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Shares Gap UpStill a Buy? - MarketBeat
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring a 178.79% Potential Upside in Rare Disease Therapeutics - DirectorsTalk Interviews
Q1 EPS Forecast for Soleno Therapeutics Raised by Analyst - MarketBeat
How Profitability from VYKAT XR and a New CFO Will Impact Soleno Therapeutics (SLNO) Investors - simplywall.st
Tangible book value per share of Soleno Therapeutics Inc – SWB:6XC - TradingView
SLNOForm S-8Securities to be offered to employees in employee benefit plans - mx.advfn.com
JPMorgan Chase & Co. Buys 140,779 Shares of Soleno Therapeutics, Inc. $SLNO - MarketBeat
Wells Fargo Cuts PT on Soleno Therapeutics (SLNO) to $110 From $114Here's Why - Finviz
Soleno Therapeutics Q4 Profitability Milestone Tests High P/E Narrative - Sahm
Soleno (SLNO) Q4 2025 Earnings Call Transcript - AOL.com
Soleno Profitability Milestone And CFO Shift Raise Valuation Questions - Yahoo Finance
Soleno Therapeutics Stock Pre-Market (+9.2%): Strong Q4 Earnings Beat & Profitability - Trefis
Soleno Therapeutics (NASDAQ:SLNO) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Price Target Cut to $110.00 by Analysts at Wells Fargo & Company - MarketBeat
Westfield Capital Management Co. LP Reduces Stock Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (PRCT), Soleno Therapeutics (SLNO) and Agilent (A) - The Globe and Mail
Soleno Therapeutics names Jennifer Fulk as CFO By Investing.com - Investing.com Australia
Soleno Therapeutics (NASDAQ:SLNO) Given New $85.00 Price Target at TD Cowen - MarketBeat
Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Soleno Therapeutics stock hits 52-week low at 37.95 USD - Investing.com Nigeria
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year LowShould You Sell? - MarketBeat
Soleno Therapeutics Names New Chief Financial Officer - marketscreener.com
Soleno Therapeutics stock hits 52-week low at 36.01 USD - Investing.com
Eli Lilly (LLY) Veteran Joins Soleno Therapeutics as CFO - GuruFocus
Soleno Therapeutics names Jennifer Fulk as CFO - Investing.com
Soleno Therapeutics Appoints Jennifer Fulk As Chief Financial Officer - Nasdaq
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer - The Manila Times
Eli Lilly veteran Jennifer Fulk to lead finances at rare disease firm Soleno - Stock Titan
Soleno Therapeutics, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Soleno Therapeutics Announces New Chief Financial Officer Appointment - TipRanks
Biopharmaceutical company Soleno Therapeutics recently announced a major personnel appointment - Bitget
New CFO for Soleno Therapeutics (NASDAQ: SLNO) as Fulk replaces Mackaness - Stock Titan
30,474 Shares in Soleno Therapeutics, Inc. $SLNO Bought by State of New Jersey Common Pension Fund D - MarketBeat
A Look At Soleno Therapeutics (SLNO) Valuation After Its Shift To Profitability And Earnings Beat - simplywall.st
Soleno Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Soleno Therapeutics Q4 2025 earnings beat expectations By Investing.com - Investing.com Australia
SLNO: VYKAT XR achieved rapid adoption, strong revenue, and profitability in its first year post-launch - TradingView
Earnings call transcript: Soleno Therapeutics Q4 2025 earnings beat expectations - Investing.com
Soleno Therapeutics (NASDAQ:SLNO) Announces Earnings Results - MarketBeat
Earnings Flash (SLNO) Soleno Therapeutics, Inc. Reports Q4 Revenue $91.7M, vs. FactSet Est of $88.8M - marketscreener.com
Soleno Therapeutics (SLNO) turns profitable after FDA-approved VYKAT XR launch in PWS - Stock Titan
Soleno Therapeutics earnings beat by $0.19, revenue topped estimates - Investing.com
Soleno Therapeutics Inc (SLNO) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):